Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.82 (+1.51%) Nasdaq
16,735.02 -2.08 (-0.01%) Bitcoin USD
68,899.70 +1,415.45 (+2.10%) CMC Crypto 200
1,489.48 +21.54 (+1.47%)
HCM Nov 2024 12.500 put
| Previous close | 1.0000 |
| Open | 1.0000 |
| Bid | 0.4000 |
| Ask | 1.0000 |
| Strike | 12.50 |
| Expiry date | 2024-11-15 |
| Day's range | 1.0000 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswireHUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that results from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were published in Nature Medicine. Updated efficacy data in key subgroups an
- GlobeNewswire
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online. Results will be presented from the registration Phase II study of fruquintinib combined wit
- GlobeNewswire
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, lead
